Oramed Pharmaceuticals Inc. announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with Glucagon-like Peptide 1 (GLP-1).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.56 USD | +0.79% |
|
-0.39% | +10.82% |
Jun. 26 | Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program | MT |
Jun. 26 | Oramed Pharmaceuticals Inc. announces an Equity Buyback for $20 million worth of its shares. | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.82% | 104M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- ORMP Stock
- News Oramed Pharmaceuticals Inc.
- Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes